Brian Stalter has been structuring and negotiating complex life sciences transactions for over 20 years. Most recently, Brian was general counsel at Cabaletta Bio, a public biotechnology company in Philadelphia focused on the development of cell therapies for the treatment of auto-immune disease. Prior to Cabaletta, Brian was vice president and assistant general counsel at Bristol-Myers Squibb (BMS), leading a team that was responsible for a broad range of corporate partnering arrangements for BMS on a worldwide basis, including licensing agreements, collaborative research and development agreements, academic collaborations and co-commercialization arrangements. During his 14-year career at BMS, Brian handled several transformative deals, including BMS’ cardiovascular alliance with Pfizer on ELIQUIS, its partnership in immuno-oncology with Ono Pharmaceutical Co. on OPDIVO and other I-O agents, with Protein Design Labs (now Abbvie) on EMPLICITI in hematology, and in neuroscience with Otsuka on ABILIFY. Prior to joining BMS, Brian was deputy general counsel at Medarex, Inc., a public biotechnology company that has since been acquired by BMS. At Medarex, Brian was responsible for similar corporate-partnering arrangements, including many collaborations leveraging Medarex’s UltiMab human antibody development technology, as well as broader corporate matters. Brian was also formerly at Schering-Plough Corporation, where he served as senior counsel, licensing, and started his career at Dewey Ballantine LLP in New York City.
Download full bio